FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person (Check all applicable) MERIT MEDICAL SYSTEMS INC MMSI **EDELMAN RICHARD W** Director 10% Owner Officer (give title Other (specify below) below) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) See Footnote (1) 1600 W. MERIT PARKWAY 06/30/2017 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable (Street) Line) **SOUTH** UT 84095 Form filed by One Reporting Person **JORDAN** Form filed by More than One Reporting (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Transaction Disposed Of (D) (Instr. 3 Code (Instr.			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1115411 4)	
Common Stock, No Par Value	06/30/2017 ⁽¹⁾		M		20,000	A	\$9.95	35,000	D		
Common Stock, No Par Value	06/30/2017(1)		S		20,000	D	\$37.619(2)	15,000	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			vative urities uired or oosed o) (Instr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- qualified stock options (right to buy)	\$13.75							08/11/2012 ⁽³⁾	08/11/2018	Common Stock	20,000		20,000	D	
Non- qualified stock options (right to buy)	\$12.91							05/23/2013 ⁽⁴⁾	05/23/2019	Common Stock	20,000		20,000	D	
Non- qualified stock options (right to buy)	\$9.95	06/30/2017		M			20,000	05/22/2014 ⁽⁵⁾	05/22/2020	Common Stock	20,000	\$0	0	D	
Non- qualified stock options (right to buy)	\$13.99							06/11/2015 ⁽⁶⁾	06/11/2021	Common Stock	25,000		25,000	D	
Non- qualified stock options (right to buy)	\$20.27							05/22/2016 ⁽⁷⁾	05/22/2022	Common Stock	25,000		25,000	D	
Non- qualified stock options (right to buy)	\$18.8							05/26/2017 ⁽⁸⁾	05/26/2023	Common Stock	25,000		25,000	D	

Explanation of Responses:

- 1. The reporting person ceased to be a director of the Issuer on May 24, 2017.
- 2. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$37.53 to 37.80, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

- 3. Became exercisable in equal annual installments of 20% commencing 08/11/2012.
- 4. Became exercisable in equal annual installments of 20% commencing 05/23/2013.
- 5. Became exercisable in equal annual installments of 20% commencing 05/22/2014. Installments scheduled for vesting after 5/22/2017 will not be exercisable.
- 6. Became exercisable in equal annual installments of 20% commencing 06/11/2015. Installments scheduled for vesting after 6/11/2017 will not be exercisable.
- 7. Became exercisable in equal annual installments of 20% commencing 05/22/2016. Installments scheduled for vesting after 5/22/2017 will not be exercisable.
- 8. Became exercisable in equal annual installments of 20% commencing 05/26/2017. Installments scheduled for vesting after 5/26/2017 will not be exercisable.

Brian G. Lloyd, Attorney-in-Fact 07/05/2017

Date

** Signature of Reporting Person

** Signature of Reporting

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.